Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.

Trial Details

NCT ID

NCT05848765

Phase

PHASE2

Sponsor

University of Birmingham

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Epcoritamab
Lenalidomide
Rituximab
Obinutuzumab
Bendamustine
Vincristine

Locations (sample)

Aberdeen, United Kingdom|57.14369,-2.09814
Belfast, United Kingdom|54.59682,-5.92541
Birmingham, United Kingdom|52.48142,-1.89983
Blackpool, United Kingdom|53.81667,-3.05
Cambridge, United Kingdom|52.2,0.11667

Key Eligibility Criteria

Biopsy proven relapsed or refractory CD20 positive, grade 1-3a follicular lymphoma (biopsy within 3 months of trial entry)
Aged 18 years or over
Advanced disease that in the opinion of the treating physician requires treatment
Patient suitable for standard available therapy at the Investigator's discretion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →